c-KIT mutations (2, 10) followed by platelet-derived growth factor receptor alpha (PDGFRA) mutations (11) were discovered and small molecule targeted therapies with tyrosine kinase inhibitors (12, 13) were developed in GIST. Here, KIT is linked to gastrointestinal stromal tumor.